Nurodin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nurodin

Quick Facts: Nurodin

Property Description
Active ingredient Cimetidine
Form Oral tablets, oral solution, solution for injection
Pharmacological class Histamine H₂-receptor antagonist (H₂-blocker)
General purpose Targeted gastric acid control
Origin Synthetic compound

Defining Nurodin: Identity and Active Composition

Nurodin is a medicinal product whose active component is the synthetic compound Cimetidine (INN), an imidazole derivative. This single-ingredient compound is available for administration via both oral and parenteral routes, including oral tablets, an oral solution, and a solution for injection.

The therapeutic use of Cimetidine has been extensively documented in clinical practice for managing conditions related to excessive stomach acid. Its foundational role and effective mechanism in controlling gastric acid secretion in various patient populations have been documented.


Pharmacological Class: Histamine H₂-Blocker

Nurodin is officially classified as a Histamine H₂-receptor antagonist, commonly known as an H₂-blocker. This classification is critical as it defines the drug’s function of operating by competitively blocking specific H₂-receptors primarily located on the cells of the stomach lining.

The H₂-blocker class represents a group of compounds designed to interrupt a key biological signal that controls the body's acid-producing functions. Its use is clinically recognized for providing effective acid suppression, a necessary action in conditions where the reduction of acid volume is required. Cimetidine, the active ingredient in Nurodin, was historically distinguished as the first commercially successful drug in this class.


General Purpose: Targeted Acid Control

The general purpose of Nurodin is to achieve sustained suppression of gastric acid secretion by blocking the chemical messenger histamine from stimulating acid output. This action inhibits the production of acid, significantly reducing both the volume and acidity of gastric fluid. This core physiological function is utilized to alleviate the discomfort and reduce the potential corrosive effects associated with excessive stomach acid, providing the overall benefit of gastric protection.

Regulatory References

  1. Cimetidine - StatPearls - NCBI Bookshelf - NIH
  2. Ranitidine-containing medicinal products - referral - EMA

What side effects are possible with Nurodin?

Possible side effects and safety information

The official safety profile for Nurodin (Cimetidine) is structured by regulatory authorities based on the frequency and type of documented adverse reactions. These effects are grouped into System-Organ Classes (SOC) and range from common, generally expected reactions to rare, clinically serious events.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to regulatory standards:

Classification Examples of Reactions
Common Headache, dizziness, tiredness, diarrhea
Uncommon Rash
Rare Thrombocytopenia, confusion, acute renal failure, bradycardia, reversible impotence, gynecomastia
Very Rare Aplastic anemia, hepatitis

These effects are associated with various organ systems, including the Nervous system (headache, dizziness), Gastrointestinal system (diarrhea), and Blood and lymphatic system (thrombocytopenia, aplastic anemia).

Serious Adverse Reactions and Safety Considerations

Official labeling documents the occurrence of rare, but clinically significant, adverse reactions. These include serious blood disorders (such as aplastic anemia), hepatotoxicity (including hepatitis), and acute renal failure. Additionally, severe central nervous system effects, such as delirium or confusional states, are also listed.

Safety notes specify that older adults and patients with renal impairment have a heightened risk for these CNS effects. Furthermore, the development of gynecomastia and reversible impotence is associated with high-dose and long-term administration, such as that used for Zollinger-Ellison Syndrome. The medicine is contraindicated for individuals with known hypersensitivity to the active ingredient, Cimetidine.

Overdose and Emergency Response

Overdose and when to seek help

When Immediate Medical Help Is Required

In case of a suspected or accidental overdose, regulatory agencies mandate that individuals contact a Poison Control Center or emergency room at once. This is an explicit requirement given the documented risks involving vital systems. The patient should receive close clinical monitoring and prompt professional assistance, as directed by official guidance.

Documented Clinical Manifestations and Risks

The official product information specifies the manifestations associated with acute overexposure. Oral ingestions ranging from 20 to 40 grams have been associated with Central Nervous System (CNS) effects, including unresponsiveness. Common signs of drug excess listed in regulatory sources include tachycardia (rapid heartbeat) and shortness of breath or dyspnea. Severe outcomes cited in official documentation include risks to cardiovascular status (such as arrhythmias and hypotension) and the potential for respiratory failure.

Official Management and Support Measures

Management of Cimetidine overdose is non-antidotal and focuses on symptomatic and supportive therapy. Initial procedural steps involve efforts to remove unabsorbed material from the gastrointestinal tract, which may include gastric lavage or induction of vomiting. In the event of documented respiratory failure, immediate measures like artificial respiration are required to stabilize the patient. Due to the involvement of vital physiological systems, continuous observation and monitoring are mandated components of the supportive care provided by health professionals.

Therapeutic Uses of Nurodin

What Nurodin Treats: Main Uses and Benefits

Nurodin is generally relevant for symptomatic support across several critical gastrointestinal domains. It is commonly used across conditions presenting with acute episodes and heightened physiological stress. It is applied in addressing conditions marked by increased physiological stress, such as duodenal ulcers and benign gastric ulcers, and is used for managing symptoms related to Gastroesophageal Reflux Disease (GERD) and manifestations of erosive esophagitis. The medication is also considered relevant across therapeutic domains involving heightened symptoms, such as the acid-related manifestations of Zollinger-Ellison Syndrome.

This medication helps address symptom clusters that may become intense or disruptive, focusing on symptoms related to inflammatory or irritative states. It offers supportive relief from the burning or aching abdominal pain characteristic of ulcers and the recurring heartburn of acid reflux. It is applied in situations involving recurrent or episodic manifestations to support the maintenance of symptom control. This supportive therapy may help ease the overall symptom burden when acid-related manifestations interfere with daily functioning.


Quick Facts: Symptomatic Relief Domains

Symptom Domain Key Benefit Clinical Context
Symptoms related to Ulceration Supportive relief for abdominal discomfort. Applicable in clinical settings that involve acute or unstable symptom patterns.
Heartburn Helps address intense, disruptive burning sensations. Used when symptoms appear suddenly or fluctuate.
Dyspepsia Contributes to improved comfort during symptomatic periods. Relevant when symptoms create noticeable physiological strain.

Regulatory References

  1. DailyMed Cimetidine Labeling

Eligibility and Restrictions for Use

Nurodin is typically used to address nutritional deficiencies, particularly those related to Vitamin B12, and as a support for nerve health, which may include conditions like diabetic neuropathy. The decision to use Nurodin, as with any medication or supplement, must be made by a healthcare provider after a full review of a patient's medical history.


Who Can Use Nurodin?

It is generally considered safe for most adults suffering from diagnosed deficiencies of Vitamin B12 or other B vitamins in its multi-vitamin formulations. It is also commonly used as an adjuvant therapy for patients experiencing neuropathic symptoms such as pain, numbness, or tingling, especially those related to diabetes.


Who Should Exercise Caution or Avoid Nurodin?

Individuals with certain pre-existing medical conditions or characteristics should consult their doctor before starting Nurodin, as it may be contraindicated or require dose adjustment.

Condition/Status Recommendation
Allergy Avoid if allergic to methylcobalamin or any other component.
Kidney/Liver Disease Use with caution; dose adjustment or monitoring may be necessary.
Leber's Disease Generally avoided, as it may worsen optic nerve damage.
Pregnancy/Breastfeeding Consult a doctor; use only if potential benefit outweighs risk.

Disclose all existing medical conditions and current medications to your healthcare provider to ensure Nurodin is a safe and appropriate treatment option for you.

What should I know about interactions with other medicines?

Nurodin's official interaction profile is structured by multiple documented mechanisms that affect the disposition of co-administered medicinal products. The compound acts as an inhibitor of several cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4, a pharmacokinetic effect that reduces the clearance of many drugs metabolized by these pathways. Furthermore, it engages in competition for renal tubular secretion, which elevates the plasma concentrations of certain agents, including Procainamide and Metformin. The resulting increase in gastric pH also alters the absorption and subsequent exposure of various acid-sensitive drugs.

Interaction severity is formally classified, with co-administration with Dofetilide, Eliglustat, Lomitapide, and Pimozide designated as contraindicated due to the severe risk of increased exposure. Other clinically significant interactions, such as those with Warfarin, Phenytoin, and Theophylline, are noted for leading to delayed elimination and increased systemic concentration. Timing-based rules require Azole Antifungals to be administered at least 2 hours prior to Cimetidine, and co-administration with Antacids should not occur simultaneously. A documented risk also exists for potentiating the myelosuppressive effects of certain chemotherapeutic agents.

Mechanism of Action

How Nurodin Works: Mechanism of Action

Antagonism of Histamine H2-Receptors

The mechanism of Nurodin (Cimetidine) is centered on the competitive blockade of Histamine H2-receptors ( H2 R), which are located on the basolateral membrane of gastric parietal cells. This action initiates a molecular cascade that intercepts the primary chemical signal that stimulates acid secretion. By acting as a competitive antagonist, the drug prevents the natural ligand, Histamine, from binding and activating the receptor.

Interruption of the Cellular Acid-Secretion Cascade

Blocking the H2 R immediately interrupts the Gs-protein signaling cascade within the parietal cell, leading to a reduction in secondary messengers like cyclic AMP (cAMP). This cellular event reduces the subsequent activity of the H^+/ K^+-ATPase (Proton Pump), which is the final common effector for acid secretion. The process modulates the signaling sequence involved in stimulated acid secretion.

Physiological Suppression of Gastric Acidity

The systemic consequence of this molecular antagonism is a reduction in the secretion of H^+ ions into the stomach lumen. This mechanism leads to a predictable physiological adjustment: an increase in gastric pH and a simultaneous decrease in the overall volume of gastric fluid, resulting in the modification of gastric fluid pH within the targeted pathway.

Dosage and Administration Information

Nurodin (Cimetidine) is an agent whose usage is based on instructions for both oral and parenteral administration, available in dosage forms such as tablets, an oral solution, and a solution for injection. The chosen route and corresponding dose are determined based on the specific condition and the patient’s clinical status.

Standardized dosing patterns are structured around specific milligram amounts and frequency. For the short-term treatment of active duodenal ulcers, regimens include 800 mg once daily at bedtime or utilizing a divided dose of 400 mg twice daily. Long-term maintenance therapy, intended for prophylaxis, is generally standardized as 400 mg taken once daily at bedtime.

The scheduling of Nurodin often aligns with meal times; for instance, the 300 mg four-times-daily regimen is prescribed to be taken with meals and at bedtime. Patients using the oral form are instructed to swallow the tablets with water. The treatment duration is typically defined as a short-term course, often four to eight weeks for initial healing, followed by a maintenance plan.

Usage guidelines also require special consideration for certain patient populations and procedural constraints. Dosage adjustments are utilized when treating patients with established renal impairment to prevent excessive systemic exposure. Additionally, guidelines stipulate that the possibility of an underlying malignancy must be excluded before initiating therapy for gastric ulceration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nurodin

The research foundation for Nurodin (Cimetidine) is rooted in the extensive data package submitted to regulatory authorities, primarily Randomized Controlled Trials (RCTs), which are a foundational study design for measuring outcomes in clinical research. The evidence focuses on what happens during defined treatment periods and what specific outcomes were measured by researchers. Research describes patterns observed in patient groups, rather than predicting individual outcomes.


Evidence for Use in Active Ulcer Disease

This section will summarize the structure of the research base, including the types of randomized controlled trials (RCTs) and systematic reviews conducted for both active duodenal ulcers and benign gastric ulcers, and what specific outcomes (such as measured healing rates and patient-reported discomfort) were explored by researchers.

Research Structure for Duodenal Ulcers

Studies exploring the study regimen's association with active duodenal ulcers have been conducted using short-term RCTs that examined specific study outcomes, including endoscopically confirmed ulcer healing rates and patient-reported changes in abdominal discomfort. The core research involved adult patients, reflecting the design of large-scale RCTs. Trials documented measurements of ulcer healing and explored whether the study regimen was associated with changes in patient-reported outcomes related to pain and abdominal discomfort experienced during the day and night.

Research Structure for Benign Gastric Ulcers

Research for benign gastric ulcers utilized controlled clinical trials and RCTs, primarily focusing on short-term treatment, typically up to 8 weeks. The studies explored outcomes related to physical discomfort and the rate of endoscopic healing of the ulcer, which was the primary measure monitored. Studies report observed patterns in ulcer size reduction and related symptom evolution in the study populations during the short-term period.


Evidence for Use in Acid Reflux and Hypersecretory States

The evidence landscape also includes studies exploring Nurodin for use in conditions characterized by functional limitations, such as managing symptoms of Gastroesophageal Reflux Disease (GERD), and in the context of rare, chronic hypersecretory conditions like Zollinger-Ellison Syndrome. Research for GERD explored patient-reported outcomes describing perceived discomfort, specifically changes in the frequency and severity of heartburn symptoms, and measurements related to the healing of lesions in the esophagus.


Documented Research Gaps and Uncertainty

The scientific literature highlights several areas where evidence is limited. A key limitation is that many primary trials were conducted decades ago; as such, comparative evidence is lacking against other available acid-reducing compounds today. Additionally, the overall long-term effects on factors like quality of life or the long-term history regarding serious complications are not fully established. Subgroup findings for certain populations, such as those with certain comorbidities, remain insufficient.

Key Studies & References

  1. Cimetidine tablet: FDA Approved Drug Products Labeling
  2. Cimetidine: drug record

Frequently Asked Questions (FAQ)

Common questions about Nurodin (FAQ)


Q: What information is available about Nurodin and breastfeeding?

Official regulatory data confirms that the active ingredient in Nurodin, Cimetidine, is present in breast milk. Regulatory data generally describes the amount an infant receives as low. Official documents also indicate that Cimetidine may lead to an increase in serum prolactin levels, which is a hormone associated with milk production.


Q: How quickly do people typically start noticing effects from Nurodin?

According to official pharmacokinetic data, the onset of action is generally observed within approximately one hour after Nurodin is taken. This period reflects when the active ingredient begins its function of reducing acid secretion.


Q: What is the expected length of time Nurodin stays in the body?

Official pharmacokinetic information indicates the half-life of Cimetidine in adults is around two hours. This duration describes the time it takes for half the concentration of the medicine to be processed by the body. However, the duration of the drug’s primary effect, which is the reduction of stomach acid, is noted to last for four to five hours following a standard dose.


Q: Is there any research evidence supporting the use of Nurodin in the long term?

While many core clinical trials examine short-term use for initial ulcer healing, regulatory documents also define specific maintenance therapy regimens. These regimens are defined in official guidelines for long-term prophylaxis (preventative treatment) after the initial healing phase has been completed.


Q: Can Nurodin cause weight gain or weight loss?

Official labeling for the active ingredient does not list weight gain as a common adverse reaction. However, official safety documentation does identify unexplained weight loss as a symptom that requires consultation with a healthcare professional, as noted in the safety documentation.


Q: Can Nurodin affect the results of common lab tests?

Regulatory notes indicate that Cimetidine can cause a transient, temporary, and reversible rise in a blood substance called serum creatinine. This happens because the drug affects how creatinine is eliminated by the kidneys, not necessarily due to a true change in kidney function.


Q: Is there a generic version of Nurodin available?

Yes, Nurodin is the brand name for the active ingredient, Cimetidine, which is also widely available as a generic medicine. Generic versions contain the same active ingredient and meet the same quality standards as the brand-name product.


Q: What about Nurodin use for people with liver function issues?

Official warnings advise caution for individuals with impaired liver function, as the liver partially metabolizes Nurodin's active ingredient. Liver impairment is also noted as a factor that can increase the risk of central nervous system (CNS) side effects.


Q: Is Nurodin safe to use while driving or operating machinery?

Official product information lists adverse reactions such as dizziness and confusion. Official information suggests that individuals consider how the medicine affects them before engaging in activities that require full mental alertness, such as driving or operating machinery.


Q: Can taking Nurodin affect fertility in men or women?

Official documentation has not established an effect on fertility in male animal studies at high doses. However, regulatory labeling does document reversible impotence as a rare side effect associated with long-term, high-dose administration.


Q: Is there a risk of withdrawal symptoms if Nurodin is suddenly stopped?

Scientific literature suggests that abrupt discontinuation of Histamine-blocking drugs can sometimes be associated with symptoms like activation, insomnia, or a mild anticholinergic withdrawal syndrome. Official patient information advises consultation regarding any changes to a regimen.


Q: Can Nurodin cause changes in blood pressure?

Official safety data lists bradycardia, which is a slowed heart rate, as a rare adverse reaction. Additionally, interaction profiles note that taking Nurodin with certain heart medications, such as beta-blockers, may increase the potential for effects such as low blood pressure (hypotension).


Q: Is Nurodin known to cause issues with vision or eyesight?

While extremely rare, isolated case reports in medical literature have described an association between the active ingredient and a reversible condition known as optic neuropathy. The incidence of this event is noted to be very low.


Q: What should be done if a dose of Nurodin is missed?

General patient guidelines for missed doses typically describe taking the dose as soon as it is remembered. If it is near the time of the next scheduled dose, general patient guidelines often mention taking only the next single dose and avoiding extra doses.


Q: Can Nurodin be taken with common pain relievers like ibuprofen or acetaminophen?

Official interaction data specifies that the active ingredient may increase the potential for liver-related toxicity when taken with acetaminophen. Specific safety statements regarding co-administration with non-steroidal anti-inflammatory drugs like ibuprofen are not present in the available regulatory text.


Q: Does Nurodin interact with alcohol, and what is the official recommendation?

Official drug interaction checkers note that the active ingredient has a minor interaction with alcohol. Official guidance typically references consulting a healthcare professional regarding alcohol consumption while using the medicine.


Q: Is Nurodin generally considered safe for children or adolescents?

Official over-the-counter labeling for the active ingredient is generally directed at adults and children who are 12 years of age and older. For any child under 12 years of age, the labeling indicates that users should consult a doctor before use.


Q: Does Nurodin affect mood or cause emotional changes?

Official safety documents list specific central nervous system (CNS) effects, such as confusion, hallucinations, and delirium. These effects are reported, particularly in older adults or those with existing kidney or liver impairment, and are generally reversible upon discontinuation.


Q: Is Nurodin used for conditions other than the primary stated uses?

Regulatory documents strictly define the approved uses for Nurodin, which include conditions such as active duodenal and gastric ulcers, Gastroesophageal Reflux Disease (GERD), and certain hypersecretory states. The medication is only formally indicated for these specific conditions.


Q: Can Nurodin be taken safely by elderly patients?

Official warnings advise caution for use in older adults due to a heightened risk of confusion and other central nervous system effects. The active ingredient is suggested to be avoided in older adults who are already experiencing or are at risk of delirium.


Q: Are there special considerations for people with heart conditions taking Nurodin?

Official interaction profiles indicate the drug can raise the blood levels of certain heart medications, such as beta-blockers and calcium channel blockers. This effect may increase the risk of cardiovascular events, including low blood pressure and a slowed heart rate.


Q: Can Nurodin affect blood sugar levels in diabetic patients?

Regulatory interaction data notes that Nurodin's active ingredient can increase the effects of certain medications used to lower blood sugar levels, such as oral hypoglycemic agents. This increase in effect may raise the potential for lowered blood sugar.


Q: Is it possible to be allergic to Nurodin?

Official regulatory labeling includes an allergy alert. It explicitly states that the product should not be used by individuals who are known to be allergic to Cimetidine, the active ingredient, or to any other acid reducers.


Q: Can Nurodin be taken by people who are lactose intolerant?

Official labeling for the active ingredient provides a list of inactive ingredients, or excipients. Depending on the specific formulation being used, the product may contain components such as lactose or corn starch.

How should Nurodin be stored and disposed of?

How to Store and Dispose of Nurodin? — Official Regulatory Information

Scope Element Required Regulatory Statement (Archetypal)
Labeled storage temperature requirements: Store in a cool, dry place. Do not store above 30 C (e.g., 86 F).
Light/moisture protection requirements: Protect from light and moisture.
Handling requirements: No special handling is required. Do not freeze.
Packaging-related storage rules: Keep the medicine in the original container or blister pack.
Child-protection storage requirements: Keep out of the sight and reach of children.
Disposal instructions: Do not dispose of via household waste or by flushing down the toilet.
Environmental or controlled-waste disposal requirements: Dispose of unused or expired medicine through an official pharmaceutical take-back program.

Official regulatory documents define storage constraints by mandating a specific temperature range and requiring protection from environmental factors like light and moisture to maintain product quality. The label strictly requires the medicine to be kept in its original packaging and securely stored away from children. Disposal must follow authorized pharmaceutical waste protocols and must not involve household trash or the wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nurodin found in:

A-Z Index: